Abbott CardioMEMS Wins FDA Approval for Patient-Facing App Features
Article excerpt
Highlighted: the sentence this signal was extracted from
Abbott announced on Oct. 5, 2026 that the U.S. Food and Drug Administration has approved updates to the CardioMEMS HF System that enable new patient-facing capabilities through the company's CardioGuide HF App. For the first time, care teams can allow U.S. CardioMEMS patients to view their pulmonary artery pressure (PAP) readings directly on their smartphones. The CardioGuide HF App is a mobile application for people living with heart failure who have an implanted CardioMEMS pulmonary artery pressure sensor. It displays a patient's own PAP readings and trends on an iOS or Android smartphone. Abbott said it plans to make the CardioGuide HF App and a companion software feature, Dynamic Treatment Plan, available later this year. Pulmonary artery pressure is the pressure of blood flowing from the right side of the heart into the lungs. According to Abbott, rising PAP is one of the earliest signs of worsening heart failure and can occur weeks before a patient experiences symptoms. For more than a decade, clinicians have used PAP readings from the CardioMEMS HF System to help identify signs of worsening heart failure and guide treatment. The CardioMEMS HF System measures PAP through a small sensor implanted permanently in the pulmonary artery. The system also includes the CardioMEMS HERO device, which patients use to take pressure readings, and the Merlin.net Patient Care Network...
Keep reading with a free account
The rest of this article, and every signal for Abbott, is in your free account.
